Novonesis A S (NVZMF) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Ladies and gentlemen, welcome to the NOVONASIS full-year financial statement for 2025 and annual report for 2025. I'm Moritz, the course call operator. I would like to remind you that all participants will be in a listen-only mode and the conference is being recorded. The presentation will be followed by a question and answer session. You can register for questions at any time by pressing star and 1 on your telephone. For operator assistance, please press star and 0. The conference must not be recorded for publication or broadcast. At this time, it's my pleasure to hand over to Tobias Cornelius Björklund, Head of Investor Relations. Please go ahead. So, thank you, Operator, and good morning, everyone, and welcome to the NovoNesis conference call for 2025. As mentioned, my name is Tobias Björklund. I'm heading up Investor Relations here at NovoNesis. In this call, our CEO, Esther Baggett, and our CFO, Rainer Lehmann, will review our performance for the year, as well as the outlook for 2026. Attending today's call, we also have Tina Feiner, EVP of Planetary Health Biosolutions, Henrik Jørg Nilsson, EVP of Human Health Biosolutions, Andrew Taylor, EVP of Food and Beverages Biosolutions, and Klaus-Krone Fuglsang, Chief Scientific Officer. The conference call will take about one hour, including Q&A. Please change to the next slide. As usual, I would like to remind you that the information presented during the call is unaudited and that management may make forward-looking statements. These statements are based on current expectations and beliefs, and they involve risks and uncertainties that could cause actual results to differ materially from those described in any forward-looking statement. With that, I am now pleased to hand you over to our CEO, Esther Bajet. Esther, pl...